Last updated: October 29, 2026
Nutropin is a discontinued recombinant human growth hormone product containing somatropin and marketed by Genentech, a Roche company. Its commercial decline resulted primarily from product discontinuation, manufacturing and supply constraints, payer pressure, and competition from newer somatropin delivery systems. Roche does not report Nutropin revenue as a standalone line item, so its financial trajectory must be assessed through product status, market-share displacement, and Roche’s broader pharmaceutical reporting.
What is Nutropin and what indications did it treat?
Nutropin is recombinant somatropin, a human growth hormone produced using recombinant DNA technology. Genentech marketed several versions, including Nutropin and the liquid formulation Nutropin AQ.
| Product |
Active ingredient |
Administration |
Primary commercial role |
| Nutropin |
Somatropin |
Subcutaneous injection |
Earlier-generation recombinant growth hormone |
| Nutropin AQ |
Somatropin |
Liquid subcutaneous injection |
Convenience-oriented formulation |
| Nutropin AQ NuSpin |
Somatropin |
Prefilled pen delivery system |
Later-generation delivery product |
Nutropin labeling covered pediatric growth hormone deficiency, chronic renal insufficiency before kidney transplantation, Turner syndrome, idiopathic short stature, and adult growth hormone deficiency, depending on the product and label version. The FDA-approved indications reflected the broader somatropin market rather than a unique mechanism of action (U.S. Food and Drug Administration [FDA], n.d.-a).
The product competed in a market where clinical differentiation between somatropin brands is limited. Commercial performance depended heavily on delivery devices, patient support, supply reliability, reimbursement, physician familiarity, and contractual access.
When did Nutropin lose commercial exclusivity?
Nutropin’s principal composition-of-matter and recombinant human growth hormone protection expired years before the product was discontinued. The product no longer had meaningful patent-based exclusivity in the United States when Genentech withdrew it from the market.
Somatropin products generally do not receive the same commercial protection profile as newer biologics with active molecule, formulation, device, and manufacturing patent layers. Nutropin’s legacy patents were directed to recombinant human growth hormone technology and product-specific implementation. Those rights did not prevent competing somatropin products from entering the market.
The commercial exclusivity timeline is best summarized as follows:
| Event |
Approximate period |
Market effect |
| Recombinant human growth hormone commercialization |
1980s |
Established Genentech as an early innovator |
| Nutropin launch and label expansion |
1990s |
Expanded Genentech’s pediatric and adult growth hormone franchise |
| Competing somatropin products gain market access |
1990s-2000s |
Reduced product-level differentiation |
| Follow-on and biosimilar competition |
2000s onward |
Increased payer and contracting pressure |
| Nutropin product discontinuation |
2010s-2020s |
Eliminated current U.S. sales opportunity |
Nutropin therefore lost effective exclusivity through a combination of patent expiry and therapeutic substitution. The primary commercial threat was not a single Paragraph IV challenge against a remaining high-value patent. It was competition from other somatropin brands and delivery platforms.
What is the Orange Book and Purple Book status of Nutropin?
Nutropin is a biologic product, so the FDA Purple Book is more relevant than the Orange Book for reference-product and biosimilar analysis. The Orange Book primarily addresses approved small-molecule drug products and patent or exclusivity information submitted for those products. Biologic reference products licensed under the Public Health Service Act are evaluated through the Purple Book framework (FDA, n.d.-b).
Nutropin’s practical regulatory position is:
- It is not a current growth hormone market leader.
- It does not have commercially meaningful remaining exclusivity.
- Its market position is not protected by an active, high-value Orange Book patent strategy.
- Future competition is governed mainly by biologic licensing, biosimilar development, product availability, reimbursement, and manufacturing economics.
Because Nutropin is discontinued, the commercial relevance of any historical listing is limited. The key issue is whether physicians, payers, and patients can obtain the product, not whether a remaining patent blocks a competing somatropin.
Why was Nutropin discontinued?
Genentech discontinued Nutropin products after the brand had become commercially disadvantaged relative to newer growth hormone products. Public product communications and FDA supply information associated Nutropin with manufacturing and supply issues. Genentech did not maintain Nutropin as a growth franchise with the same commercial profile as newer medicines in Roche’s portfolio.
The main discontinuation drivers were:
- Manufacturing complexity for a mature, lower-growth biologic.
- Supply interruptions that weakened physician and payer confidence.
- Competition from Norditropin, Genotropin, Humatrope, Omnitrope, Saizen, and other somatropin products.
- Device innovation by competitors.
- Limited ability to raise price without losing formulary access.
- A strategic shift toward higher-value oncology, immunology, neurology, and ophthalmology assets.
A discontinued product can remain clinically important to existing patients while becoming financially unattractive to its sponsor. Growth hormone treatment requires long-term supply continuity. A temporary shortage can cause treatment switching, and those switches are difficult to reverse once a competing device and reimbursement pathway are established.
How did Nutropin’s financial trajectory develop?
Roche and Genentech have not publicly reported Nutropin revenue as a separate material product line in recent annual reports. As a result, no reliable current revenue, operating margin, or cumulative-sales figure can be assigned to Nutropin from Roche’s consolidated disclosures.
The financial trajectory can be divided into four phases.
Early commercialization and franchise expansion
Nutropin benefited from the expansion of recombinant growth hormone treatment beyond severe pediatric growth hormone deficiency. Additional indications increased the addressable patient population, particularly in Turner syndrome, chronic renal insufficiency, idiopathic short stature, and adult growth hormone deficiency.
At this stage, the product had the advantages of an established brand, Genentech’s manufacturing capability, and an expanding category.
Maturity and competitive compression
The growth hormone market matured as multiple brands reached physicians and payers. Although products used the same active ingredient, manufacturers differentiated through:
- Pen and cartridge systems.
- Needle concealment and injection ergonomics.
- Refrigeration and handling characteristics.
- Patient support programs.
- Specialty pharmacy distribution.
- Contract pricing.
- Pediatric endocrinology relationships.
The commercial value of Nutropin shifted from molecule-level innovation to execution. That reduced the return on further investment in a legacy product.
Declining sales and supply disruption
As competing products secured payer contracts and developed newer devices, Nutropin became more vulnerable to volume loss. Supply interruptions accelerated this process. A physician who switches a child to another growth hormone because Nutropin is unavailable may continue using the substitute after supply returns.
The economic impact extended beyond lost prescription volume. A mature biologic with specialized manufacturing, cold-chain requirements, quality controls, and patient-support obligations can have unattractive fixed costs when volumes fall.
Discontinuation and revenue elimination
After discontinuation, Nutropin no longer contributes meaningful ongoing product revenue. Roche’s financial exposure is therefore primarily historical rather than forward-looking. The relevant financial question is opportunity cost: whether maintaining Nutropin would have generated enough gross profit to justify manufacturing, regulatory, pharmacovigilance, supply-chain, and commercial infrastructure.
Public Roche reporting supports the conclusion that Nutropin is not a separately material current revenue contributor. Roche reports major pharmaceutical products and business segments, but does not identify Nutropin as a significant current growth driver (Roche, 2023, 2024).
How large was the competitive somatropin market?
The somatropin market has several structural characteristics:
- It is a chronic-use specialty market.
- Pediatric patients often remain on treatment for years.
- Product selection is influenced by endocrinologists and payers.
- Device usability can affect adherence.
- Supply reliability is commercially important.
- Payer rebates can outweigh brand loyalty.
- Growth hormone therapy requires high-cost specialty distribution.
The principal competitors have included:
| Brand |
Company or commercial sponsor |
Competitive position |
| Norditropin |
Novo Nordisk |
Strong global scale and pen-based delivery |
| Genotropin |
Pfizer |
Established global brand and device platform |
| Humatrope |
Eli Lilly |
Long-standing U.S. somatropin franchise |
| Omnitrope |
Sandoz |
Follow-on or biosimilar-positioned competition |
| Saizen |
Merck Serono |
International somatropin competitor |
| Nutropin |
Genentech/Roche |
Discontinued legacy brand |
Novo Nordisk has had the strongest strategic positioning in the growth hormone category because it combines a large endocrine franchise, global manufacturing scale, specialty distribution, and modern injection devices. Pfizer and Eli Lilly also benefited from established pediatric endocrinology relationships.
What generic or biosimilar entry risks affected Nutropin?
Traditional generic substitution does not apply to somatropin in the same way it applies to small-molecule tablets. Somatropin is a biologic, and competing products generally require a biologics license or an applicable follow-on pathway.
The principal competitive categories were:
- Follow-on somatropin products.
- Biosimilar somatropin products.
- Reference-product competitors with distinct delivery systems.
- International products approved under regional biosimilar rules.
- Compounded or alternative growth hormone products in limited settings.
Omnitrope was one of the most important early follow-on somatropin products. Its entry demonstrated that a competitor could challenge incumbent growth hormone brands without duplicating every commercial element of the reference product. Over time, biosimilar regulation increased payer leverage and reduced the ability of mature products to preserve premium pricing.
Nutropin’s risk was therefore substitution risk rather than a single litigation-driven generic launch. Once competing somatropin products became clinically acceptable and reimbursable, Nutropin’s price and volume protection weakened.
Did Paragraph IV litigation affect Nutropin?
There is no major, commercially determinative Paragraph IV litigation narrative associated with Nutropin comparable to the patent disputes surrounding blockbuster small-molecule drugs.
That result follows from the product’s regulatory category and patent position:
- Nutropin was a biologic rather than a conventional ANDA product.
- Somatropin competition developed through biologic and follow-on pathways.
- Historical product and platform patents had largely expired before discontinuation.
- Device and formulation protections were not sufficient to preserve a durable commercial moat.
Any patent disputes involving recombinant growth hormone technology, formulations, or delivery devices would have had less effect on Nutropin’s late-stage economics than manufacturing performance, supply continuity, and payer contracting.
What formulation and device patents protected Nutropin?
Nutropin’s commercial differentiation relied more on formulation and delivery technology than on a new active ingredient. Product-related protection could include:
- Liquid somatropin formulations.
- Stabilization systems.
- Cartridge designs.
- Pen injectors.
- Dose-delivery mechanisms.
- Packaging and cold-chain configurations.
These protections are narrower than composition-of-matter protection. A competitor can often avoid a device patent by using a different injector, cartridge, concentration, or formulation architecture. Device patents also have shorter practical value when physicians and payers can switch patients to an alternative product.
Nutropin AQ and Nutropin AQ NuSpin were intended to reduce the inconvenience associated with reconstituted growth hormone. That design strategy was commercially rational, but it did not create a lasting barrier once competitors introduced comparable liquid products and injection pens.
How strong was the Nutropin patent estate?
Nutropin’s late-stage patent estate was weak as a commercial exclusivity mechanism.
| Patent-estate category |
Strategic value at discontinuation |
| Recombinant somatropin composition and production |
Low, because core rights were mature or expired |
| Liquid formulation |
Moderate historically, but narrow and design-aroundable |
| Pen and cartridge device |
Moderate for product differentiation |
| Method-of-use claims |
Limited, because many indications were established across the class |
| Manufacturing know-how |
Potentially relevant operationally, but not a durable market barrier |
| Regulatory exclusivity |
No meaningful remaining protection after product maturity |
The strongest residual barriers were likely operational rather than legal. Manufacturing a consistent injectable biologic at commercial scale requires validated processes, quality systems, cold-chain logistics, and regulatory maintenance. Those requirements can deter small entrants, but they do not protect a large incumbent from established pharmaceutical competitors.
What manufacturing and supply-chain barriers affected the product?
Somatropin manufacturing requires tight control over protein expression, purification, formulation, sterility, potency, aggregation, and container closure. The product also requires temperature-controlled distribution and specialized quality testing.
For a mature product, these requirements create an unfavorable cost structure when volume declines. Fixed costs remain while revenue falls. A manufacturing interruption can produce:
- Backorders and pharmacy substitution.
- Patient switching.
- Lost payer contracts.
- Higher per-unit costs.
- Increased regulatory workload.
- Reduced confidence among endocrinologists.
The Nutropin case illustrates a central feature of mature biologic markets: supply reliability can be as important as patent protection. A product with no meaningful patent moat and intermittent availability has limited ability to recover share through price or promotion.
What FDA regulatory status does Nutropin have?
Nutropin was FDA-approved somatropin therapy, but the marketed product has been discontinued. Discontinuation does not erase the historical approval record. It does mean that current commercial availability, distribution, and prescribing access are constrained or absent.
The FDA distinguishes between a product being approved and a product being actively marketed. A product can remain in regulatory databases while no longer generating sales. The relevant commercial status is whether the sponsor is manufacturing and distributing the product through normal channels.
For current growth hormone treatment, physicians generally use available products such as Norditropin, Genotropin, Humatrope, Omnitrope, and other approved somatropin products according to indication, payer policy, and supply availability.
What was Nutropin’s revenue exposure to Roche?
Nutropin’s direct revenue exposure to Roche is now negligible. Roche’s annual reporting does not identify Nutropin as a separately material product in its current pharmaceutical sales tables. The company’s financial exposure shifted from revenue generation to the cost of maintaining or exiting a mature biologic platform.
The likely economic effects of discontinuation were:
- Elimination of Nutropin manufacturing revenue.
- Reduction in product-specific commercial and medical costs.
- Lower regulatory-maintenance expense.
- Potential restructuring or inventory charges.
- Transfer of patients to competing growth hormone products.
- No material impact on Roche’s consolidated revenue base.
Nutropin was commercially important within its therapeutic class but not large enough in Roche’s portfolio to influence group-level financial performance after discontinuation.
How does Nutropin compare with current growth hormone competitors?
| Factor |
Nutropin |
Norditropin |
Genotropin |
Humatrope |
Omnitrope |
| Current commercial availability |
Discontinued |
Active |
Active |
Active |
Active in relevant markets |
| Active ingredient |
Somatropin |
Somatropin |
Somatropin |
Somatropin |
Somatropin |
| Core differentiation |
Legacy liquid and pen platforms |
Pen, scale, endocrine franchise |
Established brand and delivery systems |
Established U.S. brand |
Follow-on/biosimilar positioning |
| Patent value today |
Limited |
Product and device-specific |
Product and device-specific |
Product and device-specific |
Competition-oriented |
| Payer leverage |
None after discontinuation |
High, depending on contract |
Established |
Established |
Potentially strong through price |
| Main risk |
No supply or commercial platform |
Biosimilar and payer pressure |
Mature-market erosion |
Mature-market erosion |
Reimbursement and interchangeability |
Nutropin’s main disadvantage was not inferior pharmacology. It was the loss of a viable commercial platform.
What generic launch scenarios remain relevant?
A direct Nutropin generic launch is not the central scenario because Nutropin is discontinued and somatropin is regulated as a biologic. The relevant scenarios are:
- Additional biosimilar somatropin launches that reduce class pricing.
- Payer-driven switching from branded products to lower-cost alternatives.
- New long-acting growth hormone products that reduce injection frequency.
- Device innovation that improves adherence and reduces administration burden.
- Supply-driven substitution among existing somatropin brands.
Long-acting growth hormone products pose a greater strategic threat to legacy daily-injection brands than conventional biosimilar entry alone. Products such as once-weekly growth hormone therapies compete on convenience, adherence, and persistence rather than only price.
Key Takeaways
- Nutropin is a discontinued Genentech/Roche somatropin product.
- Its core patent-based exclusivity expired before commercial withdrawal.
- Nutropin’s late-stage market decline reflected competition, supply problems, device obsolescence, and payer pressure.
- Roche does not report Nutropin revenue separately, and the product is not a material current revenue contributor.
- Biologic and biosimilar competition, rather than Paragraph IV litigation, shaped the product’s competitive decline.
- The strongest remaining barriers in the somatropin market are manufacturing quality, supply reliability, payer access, and delivery technology.
- Current competitive pressure comes from Norditropin, Genotropin, Humatrope, Omnitrope, and long-acting growth hormone products.
- Nutropin’s commercial failure was primarily a portfolio and lifecycle-management outcome, not a clinical failure of somatropin.
FAQs about Nutropin’s market and financial outlook
Is Nutropin still available in the United States?
Nutropin is no longer an actively marketed U.S. growth hormone product. Current treatment generally relies on other FDA-approved somatropin products or newer long-acting growth hormone therapies.
Did Roche sell Nutropin revenue as part of Genentech’s financial results?
Historical Nutropin sales were included within Genentech and Roche pharmaceutical results, but Roche does not separately disclose current Nutropin revenue in its principal annual-report product tables.
Is Nutropin interchangeable with Norditropin or Genotropin?
Not automatically. All contain somatropin, but product selection depends on the approved indication, formulation, device, payer requirements, prescribing decisions, and applicable substitution rules.
Are there Nutropin biosimilars?
There are competing somatropin products, including follow-on and biosimilar-positioned products in certain jurisdictions. These products compete with the same therapeutic category but do not necessarily enter through a direct Nutropin-specific substitution pathway.
Does Nutropin have remaining patent value outside the United States?
Any remaining foreign patent or regulatory rights would have to be assessed jurisdiction by jurisdiction. For commercial purposes, Nutropin’s global value is constrained by discontinuation, mature somatropin competition, and the availability of alternative products.
References
-
Roche. (2023). Annual report 2023. Roche Holding Ltd.
-
Roche. (2024). Annual report 2024. Roche Holding Ltd.
-
U.S. Food and Drug Administration. (n.d.-a). Nutropin AQ prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (n.d.-b). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.
-
World Health Organization. (2022). Guidelines on evaluation of similar biotherapeutic products. World Health Organization.
